drugset

Drugs / PhOx430

Follow last change Oct 2025 re-read 3 minutes ago

PhOx430

Developed for: glioblastoma · metastatic malignant neoplasm
Investigated by: Phost'In Therapeutics

Trials 1

today NCT05495295 · Ph 1

2023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05495295	Jul 2022 → Nov 2024 overdue	glioblastoma, metastatic malignant neoplasm	Phost'In Therapeutics	Recruiting	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2022-06-07	Phost'In Therapeutics	Regulatory Phost’in Therapeutics announces approval of French and Italian Health Agency for a first European clinical trial application in patients with advanced solid tumors, in collaboration with Foundation Gianni Bonnadona phostin.com ↗

All press releases naming this drug 4 releases

Date	Issuer	Release
2025-10-02	Phost'In Therapeutics	Phost’in Therapeutics and the Gianni Bonadonna Foundation To Present First Clinical Data on PhOx430, a First-In-Class GnT-V Inhibitor, at ESMO 2025 phostin.com ↗
2023-08-25	Phost'In Therapeutics	Taiho Pharmaceutical and Phost’in Therapeutics announce an Option and License Agreement on the First-in-Class GnT-V inhibitor PhOx430 phostin.com ↗
2022-09-14	Phost'In Therapeutics	Phost’in Therapeutics and the Gianni Bonadonna Foundation announce First Patients Dosed with the First-In-Class PhOx430 in an adaptive Phase I/II in patients with Advanced Solid Tumors phostin.com ↗
2022-06-07	Phost'In Therapeutics	Phost’in Therapeutics announces approval of French and Italian Health Agency for a first European clinical trial application in patients with advanced solid tumors, in collaboration with Foundation Gianni Bonnadona phostin.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	PhOx430	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05495295 ↗
Action	Inhibit	“acetylglucosaminyltransferase V inhibitor PhOx430” NCT05495295 ↗
Route	Oral	“PhOx430 will be administered orally twice a day (bid), at a 12-hour interval” NCT05495295 ↗